These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

995 related articles for article (PubMed ID: 32102694)

  • 21. Biomarkers for Checkpoint Inhibition.
    Weber JS
    Am Soc Clin Oncol Educ Book; 2017; 37():205-209. PubMed ID: 28561695
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy.
    Davoli T; Uno H; Wooten EC; Elledge SJ
    Science; 2017 Jan; 355(6322):. PubMed ID: 28104840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CAMOIP: a web server for comprehensive analysis on multi-omics of immunotherapy in pan-cancer.
    Lin A; Qi C; Wei T; Li M; Cheng Q; Liu Z; Luo P; Zhang J
    Brief Bioinform; 2022 May; 23(3):. PubMed ID: 35395670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment.
    Zemek RM; De Jong E; Chin WL; Schuster IS; Fear VS; Casey TH; Forbes C; Dart SJ; Leslie C; Zaitouny A; Small M; Boon L; Forrest ARR; Muiri DO; Degli-Esposti MA; Millward MJ; Nowak AK; Lassmann T; Bosco A; Lake RA; Lesterhuis WJ
    Sci Transl Med; 2019 Jul; 11(501):. PubMed ID: 31316010
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Biomarkers for Immunotherapy Based on the Local Microenvironment of Gastric Cancer].
    Tanaka H; Yamakoshi Y; Sakimura C; Mori T; Deguchi S; Miki Y; Yoshii M; Tamura T; Toyokawa T; Muguruma K; Ohira M
    Gan To Kagaku Ryoho; 2020 Sep; 47(9):1292-1297. PubMed ID: 33130686
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pooled in vivo screens for cancer immunotherapy target discovery.
    Lane-Reticker SK; Manguso RT; Haining WN
    Immunotherapy; 2018 Mar; 10(3):167-170. PubMed ID: 29370725
    [No Abstract]   [Full Text] [Related]  

  • 27. Immune-gene signature: a new tool for patient selection for checkpoint inhibitors?
    Sobhani N; Corona SP; Roviello G; Bagby S; D'Angelo A; Iezzi G; Generali D
    Future Oncol; 2020 Jul; 16(19):1327-1330. PubMed ID: 32396404
    [No Abstract]   [Full Text] [Related]  

  • 28. Immunomodulatory MicroRNAs in cancer: targeting immune checkpoints and the tumor microenvironment.
    Omar HA; El-Serafi AT; Hersi F; Arafa EA; Zaher DM; Madkour M; Arab HH; Tolba MF
    FEBS J; 2019 Sep; 286(18):3540-3557. PubMed ID: 31306553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subgrouping breast cancer patients based on immune evasion mechanisms unravels a high involvement of transforming growth factor-beta and decoy receptor 3.
    Bou-Dargham MJ; Liu Y; Sang QA; Zhang J
    PLoS One; 2018; 13(12):e0207799. PubMed ID: 30513096
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of Circulating Tumor DNA for Cancer Immunotherapy.
    Snyder A; Morrissey MP; Hellmann MD
    Clin Cancer Res; 2019 Dec; 25(23):6909-6915. PubMed ID: 31285372
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ARID1A deficiency and immune checkpoint blockade therapy: From mechanisms to clinical application.
    Hu G; Tu W; Yang L; Peng G; Yang L
    Cancer Lett; 2020 Mar; 473():148-155. PubMed ID: 31911080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Network analysis of gene essentiality in functional genomics experiments.
    Jiang P; Wang H; Li W; Zang C; Li B; Wong YJ; Meyer C; Liu JS; Aster JC; Liu XS
    Genome Biol; 2015 Oct; 16():239. PubMed ID: 26518695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors.
    Dammeijer F; Lau SP; van Eijck CHJ; van der Burg SH; Aerts JGJV
    Cytokine Growth Factor Rev; 2017 Aug; 36():5-15. PubMed ID: 28693973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor immune evasion: insights from CRISPR screens and future directions.
    Djajawi TM; Wichmann J; Vervoort SJ; Kearney CJ
    FEBS J; 2024 Apr; 291(7):1386-1399. PubMed ID: 37971319
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of high tumor mutational burden in solid tumors and challenges for biomarker application.
    McNamara MG; Jacobs T; Lamarca A; Hubner RA; Valle JW; Amir E
    Cancer Treat Rev; 2020 Sep; 89():102084. PubMed ID: 32738738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TIP: A Web Server for Resolving Tumor Immunophenotype Profiling.
    Xu L; Deng C; Pang B; Zhang X; Liu W; Liao G; Yuan H; Cheng P; Li F; Long Z; Yan M; Zhao T; Xiao Y; Li X
    Cancer Res; 2018 Dec; 78(23):6575-6580. PubMed ID: 30154154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.
    Dong ZY; Wu SP; Liao RQ; Huang SM; Wu YL
    Tumour Biol; 2016 Apr; 37(4):4251-61. PubMed ID: 26779629
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor Immunotherapy.
    Lagos GG; Izar B; Rizvi NA
    Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-11. PubMed ID: 32315237
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.
    Negrao MV; Lam VK; Reuben A; Rubin ML; Landry LL; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Gibbons DL; Wistuba II; Papadimitrakopoulou V; Glisson BS; Blumenschein GR; Lee JJ; Heymach JV; Zhang J
    J Thorac Oncol; 2019 Jun; 14(6):1021-1031. PubMed ID: 30780001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.